Showing 1 posts of 16 posts found.
An FDA committee has recommended Sanofi-Aventis' new atrial fibrillation treatment Multaq, the company's most important late-stage drug. The FDA cardiovascular …
Lonza and Engitix partner to develop next-generation antibody-drug conjugates
Simris Group appoints Tiffany J Vora as Strategic Advisor
Cizzle Biotechnology expands US rollout of lung cancer blood test
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide